In an interview with Targeted Oncology, Meredith McKean, MD, MPH of Sarah Cannon Research Institute reviewed the recent changes to the U.S. Preventive Services Task Force skin cancer screening guidelines, and discussed advances in the skin cancer treatment paradigm for those who could not prevent the disease.
In an interview with Targeted Oncology, Tycel Phillips, MD, discussed what led to the FDA approval of subcutaneous epcoritamab for patients with relapsed/refractory diffuse large B-cell lymphoma and how it adds to the current treatment landscape.
According to interim phase 2 results, GEN-001 in combination with avelumab has a significant objective response rate in patients with gastric and gastroesophageal junction adenocarcinoma.
Phase 3 results from the combination of rivoceranib and camrelizumab have excited investigators enough to seek FDA approval for patients with unresectable hepatocellular carcinoma.
In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.
In an interview with Targeted Oncology™, Andrew J. Armstrong, MD gave a first-hand perspective on the discussion held during the recent ODAC meeting and explained what the discussion and vote mean for the future of olaparib plus abiraterone in metastatic castration-resistant prostate cancer.
Development of PYX-201 in advanced solid tumors is underway, and the drug has grabbed the FDA's attend with a phase 1 study in pancreatic cancer.
FDA approval has not been granted to N-803 for the treatment of Bacillus Calmette–Guérin-unresponsive non-muscle-invasive bladder cancer carcinoma in situ.
Real-world evidence support the use of venetoclax-based regimens for patients with chronic lymphocytic leukemia based the consistent efficacy shown between the real-world and clinical trial data.
In an interview with Targeted Oncology, Samer A. Srour, MD, discussed the results from the phase 3 TRAVERSE study and the potential role of chimeric antigen receptor T-cell therapy in renal cell carcinoma.
In the past 7 years, treatment for patients with non–small cell lung cancer has increased by over 100%, according to real-world data presented at iSPOR 2023.
Study findings presented at iSPOR 2023 reveal a substantial economic burden related to metastatic non–small cell lung cancer care, which impacts both patients and the healthcare system.
New results from ORIENT-31 show a sustained progression-free survival benefit and overall survival improvement trend in patients with EGFR-mutant non–small cell lung cancer who failed a tyrosine kinase inhibitor previously.
A study looked into what drives patient preference for treatment with certain BRAF/MEK inhibitors for BRAF V600E/K-mutant melanoma.
Phase 2 study results further demonstrate the promise of using belzutifan in combination with cabozantinib for the treatment of patients with advanced clear cell renal cell carcinoma.
In an interview with Targeted Oncology, Reshma Mahtani, DO, discussed the key breast cancer topics during the Miami Cancer Institute Women’s Cancer Symposium and her presentation regarding HER2-positive breast cancer .
In an interview with Targeted Oncology, Prerna Mewawalla discussed the role of bispecific antibodies in multiple myeloma treatment and options to consider before patients reach the relapsed/refractory setting.
Results from the phase 3 QuANTUM-First study create a position for quizartinib plus chemotherapy in the FLT3-ITD-positive acute myeloid leukemia armamentarium.
The Oncologic Drugs Advisory Committee has discussed the approval application for olaparib plus abiraterone and prednisone or prednisolone for patients with metastatic castration-resistant prostate cancer and voted on its potential future.
Additional findings from KEYNOTE-826 reveal no negative health-related quality-of-life impact when using pembrolizumab plus chemotherapy with or without bevacizumab.
In an interview with Targeted Oncology, John Nakayama, MD discussed 2 recently reported, practice-changing studies in endometrial cancer, and where the field is heading.
In season 4, episode 5 of Targeted Talks, Alice P. Chen, MD, discusses important studies that are investigating treatment options for alveolar soft part sarcoma.
According to Alice P. Chen, MD, the phase 2 study of atezolizumab alone or atezolizumab plus bevacizumab has a unique design.
The FDA continues to push forward PSMA-targeted therapies to address unmet needs for patients with metastatic castration-resistant prostate cancer.
Investigators of the phase 2 KRYSTAL-1 have reported important findings that may be practice-changing for oncologists who treat various KRAS G12C-mutant solid tumors, in the future.
Researchers are backing further investigation of 60 mg selinexor plus ruxolitinib based on positive phase 1/2 findings presented at the AACR Annual Meeting 2023.
The phase 3 CheckMate 914 study has missed its primary end point, and the lack of efficacy of nivolumab plus ipilimumab over placebo in the study has led investigators to refer oncologists back to the standard of care, pembrolizumab, as seen in KEYNOTE-564.
In an interview with Targeted Oncology, Jones T. Nauseef, MD, PhD, discussed the investigational PSMA targeted therapy, 225Ac-J591, and results from a phase 1 study.
On the heels of a positive ODAC vote, polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone is now FDA-approved.
The combination of botensilimab and balstilimab is moving down the FDA pipeline and may become an approved treatment for non-microsatellite instability-high and deficient mismatch repair metastatic colorectal cancer in the future.